ÿþ<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <!-- DW6 --> <head> <!-- Copyright 2005 Macromedia, Inc. All rights reserved. --> <title>Silenseed.com - siRNA</title> <meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1" /> <link rel="stylesheet" href="mm_health_nutr.css" type="text/css" /> <script language="JavaScript" type="text/javascript"> //--------------- LOCALIZEABLE GLOBALS --------------- var d=new Date(); var monthname=new Array("January","February","March","April","May","June","July","August","September","October","November","December"); //Ensure correct for language. English is "January 1, 2004" var TODAY = monthname[d.getMonth()] + " " + d.getDate() + ", " + d.getFullYear(); //--------------- END LOCALIZEABLE --------------- </script> <style type="text/css"> <!-- .style1 { font-family: "Gill Sans MT Condensed"; font-size: 48px; } .style7 { font-family: Helvetica-Condensed; color: #DFE0F1; } .style8 { color: #4A5367; font-size: 14px; } body { background-color: #DFE0F1; } .style9 { font-family: Helvetica-Condensed; color: #CCCCFF; } .style13 {color: #DFE0F1} h1{font-size: 19px;} --> </style> </head> <body> <table width="100%" border="0" cellpadding="0" cellspacing="0"> <tr bgcolor="#D5EDB3"> <td rowspan="2" align="right" bgcolor="#A9B6D9">&nbsp;</td> <td rowspan="2" align="right" bgcolor="#A9B6D9"><div align="left"><img src="silenseed 4.jpg" width="153" height="71" /></div></td> <td width="558" height="50" align="center" valign="bottom" nowrap="nowrap" bgcolor="#A9B6D9" id="logo">&nbsp;</td> <td width="283" bgcolor="#A9B6D9">&nbsp;</td> </tr> <tr bgcolor="#D5EDB3"> <td height="39" align="center" valign="top" bgcolor="#A9B6D9" id="tagline">&nbsp;</td> <td width="283" bgcolor="#A9B6D9">&nbsp;</td> </tr> <tr bgcolor="#99CC66"> <td bgcolor="#4A5367">&nbsp;</td> <td height="33" colspan="3" bgcolor="#4A5367" id="dateformat"> <a href="index.html"><span class="style13">HOME</span></a> / <a href="siRNA.html"><span class="style13">SIRNA</span></a> / <a href="People.html"><span class="style13">PEOPLE</span></a> / <a href="Contact.html"><span class="style13">CONTACT US</span></a> </td> </tr> <tr> <td height="2" colspan="4"><img src="mm_spacer.gif" alt="" width="1" height="2" border="0" /></td> </tr> <tr> <td width="103" height="214" bgcolor="#DFE0F1">&nbsp;</td> <td colspan="2" valign="top" bgcolor="#DFE0F1">&nbsp;<br /> &nbsp;<br /> <table border="0" cellspacing="0" cellpadding="2" width="678"> <tr> <td width="674" height="139" class="bodyText"> <h1>siRNA</h1> <p class="style8">Short interfering RNA (siRNA), discovered by the Nobel Prize laureates Fire and Mello in 1998 and proclaimed in 2002 by Science as "the discovery of the year"; is considered today the most promising platform for novel therapies to treat a variety of illness. Specifically, variety of  non-druggable targets that are not amenable to conventional therapeutics such as small molecules, proteins, or monoclonal antibodies potentially could be treated by siRNAs. The siRNA molecules of a vast range of types can be synthesized and administrated to the body to induce specific silencing of the target disease genes, resulting with knocking down the target protein and finally the death of the cell. In the last years preclinical studies and early clinical studies have demonstrated the potential of siRNAs for treatment of Aged-related macular degeneration (AMD), Acute Renal Failure (ARF), cancer, viral infections, autoimmune diseases, neurodegenerative diseases and additional indications. </p> <p class="style8">However, while the siRNA revolution demonstrates successful achievements, it became evident that the main obstacle is the delivery of such drugs. The actual use of siRNAs for human therapy is still plagued by the lack of safe and effective methods to deliver siRNA to desired tissues and the target cell within the body. siRNAs are rapidly degraded in blood and therefore must be shielded if administrated systemically. Shielding technologies include encapsulation within nano-particles, association with nano-carriers and chemical modifications of the siRNA molecules. Additional challenge in non-local administration is targeting of the siRNAs to the diseased site and the target cells. siRNA carriers that meet such requirements also are tightly constrained by dimension, they should be sufficiently large to avoid renal clearance, but small enough to penetrate the cell membrane. Moreover, the penetration of these carriers into the cell is derived by creating a 'cell-within-cell' called endosome, then such an endosome must be disrupted, and still release a sufficient amount of non-degraded siRNA molecules to enable significant nock down of targeted proteins. . It was also demonstrated that siRNA molecules need to be supplied to the target tissue continuously along many weeks, and optimally at a constant dose. High dose can derive toxic response while low dose become inefficient. </p> <p class="style8">To meet these requirements a variety of systemic and direct siRNA delivery methods have been developed. In both cases usually single or repeated injections are involved yielding rapid decline and fluctuation in dose. Systemic administrations also suffer from the very high amount of drug required to be injected, which is very costly and associated with unwanted response derived by the immune system to the high stream of such siRNA molecules and siRNA carriers. </p> <p class="style8">Silenseed developed a novel siRNA delivery technology tailored for treatment of variety of diseases of which the treatment can be supplied locally at the target site. Amongst are cancer diseases with solid tumors of various types, treatments of ill glands, localized chronic pain and tissues exhibit cell degeneration. In the Silenseed solution siRNA molecules are shielded against degradation by a biopolymeric matrix at the target site for months and supplied continuously at the optimized dose. Pre-clinical studies strongly evident the potential of this siRNA-based technology to become a highly efficient cure of illness including pancreatic cancer. </p> </td> </tr> </table> </td> <td width="283" bgcolor="#DFE0F1">&nbsp;</td> </tr> <tr> <td width="103" bgcolor="#DFE0F1">&nbsp;</td> <td width="99" bgcolor="#DFE0F1">&nbsp;</td> <td width="558" bgcolor="#DFE0F1">&nbsp;</td> <td width="283" bgcolor="#DFE0F1">&nbsp;</td> </tr> </table> </body> </html>